Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:50:41 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Grant Shapps vows he WILL find more planes for mass parachute drop to mark 80th anniversary of D
Next:DR MARTIN SCURR: How losing your hearing may cause dementia
You may also like
- It's no wonder parents are taking their children on holiday during term time! Sky
- China, Indonesia set to deepen ties
- French health foundation's cooperation commended
- Trilateral talks to bolster ties
- Sports betting roundup: Xander Schauffele's final putt pays off for bettors
- FM: China marks new opportunities for Australia
- Beijing strongly protests Manila's recent remarks
- Pressure mounts on Israel to spare Rafah
- Patrick Reed withdraws from US Open qualifying and ends streak of playing the majors